APA (7th ed.) Citation

Lindemann, K., Kristensen, G., Mirza, M. R., Davies, L., Hilpert, F., Romero, I., . . . Pujade-Lauraine, E. (2016). Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: Analysis of the AURELIA trial. Annals of Oncology, 27(8), 1505. https://doi.org/10.1093/annonc/mdw238

Chicago Style (17th ed.) Citation

Lindemann, K., et al. "Poor Concordance Between CA-125 and RECIST at the Time of Disease Progression in Patients with Platinum-resistant Ovarian Cancer: Analysis of the AURELIA Trial." Annals of Oncology 27, no. 8 (2016): 1505. https://doi.org/10.1093/annonc/mdw238.

MLA (9th ed.) Citation

Lindemann, K., et al. "Poor Concordance Between CA-125 and RECIST at the Time of Disease Progression in Patients with Platinum-resistant Ovarian Cancer: Analysis of the AURELIA Trial." Annals of Oncology, vol. 27, no. 8, 2016, p. 1505, https://doi.org/10.1093/annonc/mdw238.